Clearmind Medicine Inc. has announced the initiation of a Phase I/IIa clinical trial for its proprietary drug candidate, CMND-100, aimed at treating Alcohol Use Disorder (AUD). The trial marks a significant step as the first participant has been dosed under controlled clinical settings. This multinational, multicenter study, conducted at prominent institutions such as Yale School of Medicine and Johns Hopkins University, seeks to establish the safety and optimal dosing of CMND-100. Additionally, it will explore early signals of efficacy, including reductions in alcohol consumption and cravings. The results of this trial have not yet been presented, as the study is ongoing.